| Identification | Back Directory | [Name]
2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester | [CAS]
84110-34-9 | [Synonyms]
(3aS,4S,6S,7aR)
-3a,5,5-trimethyL
Bortezomib Impurity 50
(3aS,4S,6S,7aR)-2-IsobutyL
hexahydro-4,6-methanobenzo[d][1,3,2]dioxaboroL
Bortezomib intermediate
(+)-Pinanediol isobutanol borate
2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester
(2-Methyl propyl) boronic acid (1S,2S,3R,5S ) -(+) -2,3-pinanediol ester
-2-Isobutyl-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole
(1S,2S,6R,8S)-4-isobutyl-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0<
(3aS,4S,6S,7aR)-2-Isobutyl-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole
(3aS,4S,6S,7aR)-2-Isobutyl-3a,5,5-triMethylhexahydro-4,6-Methanobenzo[d][1,3,2]dioxaborole
(1S,2S,6R,8S)-2,9,9-trimethyl-4-(2-methylpropyl)-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decane
2-(2-methylpropyl)-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole
4,6-Methano-1,3,2-benzodioxaborole, hexahydro-3a,5,5-trimethyl-2-(2-methylpropyl)-, (3aS,4S,6S,7aR)-
2-Methylpropaneboronic acid (1S,2S,3R,5S)-(+)-2,3-pinanediol ester
(3aS,4S,6S,7aR)-2-Isobutyl-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole | [Molecular Formula]
C14H25BO2 | [MDL Number]
MFCD09837626 | [MOL File]
84110-34-9.mol | [Molecular Weight]
236.16 |
| Chemical Properties | Back Directory | [Boiling point ]
272.3±9.0℃ (760 Torr) | [density ]
0.97±0.1 g/cm3 (20 ºC 760 Torr) | [Fp ]
118.5±18.7℃ | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [form ]
liquid | [color ]
colorless | [Optical Rotation]
Consistent with structure |
| Hazard Information | Back Directory | [Uses]
suzuki reaction | [Synthesis]
GENERAL STEPS: A reaction mixture of (1S,2S,3R,5S)-(+)-2,3-pinanediol (6.9 g) with isobutylboronic acid (4.4 g) in diethyl ether (49.3 mL) was stirred at room temperature for 23 hours. After the reaction was completed, anhydrous sodium sulfate (16.5 g) was added to dry the reaction mixture. The sodium sulfate was removed by filtration and the filter cake was washed with diethyl ether (69.4 mL). The organic phases were combined and concentrated under reduced pressure to give a colorless oily product (9.9 g, 100% GC purity, 97.2% yield). Mass spectrum (MS, m/z): 236, 221, 195, 167, 140, 134, 83, 67, 55, 43; 1H-NMR (DMSO-d6, δ): 4.27 (1H, dd, J = 2.1 Hz, 8.7 Hz), 2.30 (1H, m), 2.18 (1H, m), 1.96 (1H, t, J = 5.4 Hz ), 1.86 (1H, m), 1.79 (1H, sx, J = 6.8 Hz), 1.69 (1H, m), 1.30 (3H, s), 1.25 (3H, s), 1.02 (1H, d, J = 10.6 Hz), 0.9 (3H, d, J = 6.6 Hz), 0.81 (3H, s), 0.69 (2H, m). | [References]
[1] Patent: WO2009/4350, 2009, A1. Location in patent: Page/Page column 9
[2] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 4, p. 1018 - 1029 |
|
|